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Does evaluation of tumour budding in diagnostic biopsies have a clinical relevance?
A systematic review
Abstract: Tumour budding has emerged as a
promising prognostic marker in many cancers. We
systematically reviewed all studies that evaluated
tumour budding in diagnostic biopsies. We conducted
a systematic review of PubMed, MEDLINE, Scopus,
Web of Science and Cochrane library for all articles
that have assessed tumour budding in diagnostic (i.e.
pretreatment or pre-operative) biopsies of any tumour
type. Two independent researchers screened the
retrieved studies, removed duplicates, excluded irrele-
vant studies and extracted data from the eligible stud-
ies. A total of 13 reports comprising 11 cohorts were
found to have studied tumour budding in diagnostic
biopsies. All these reports showed that evaluation of
tumour budding in diagnostic biopsies was easily
applicable. A strong association was observed
between tumour budding score in diagnostic biopsies
and corresponding surgical samples. Evaluation of
tumour budding in diagnostic biopsies had a signifi-
cant prognostic value for lymph node metastasis and
patient survival. In all studies, tumour budding was a
valuable marker of tumour aggressiveness and can be
evaluated in technically satisfactory diagnostic biop-
sies. Thus, the assessment of tumour budding seems
to identify the behaviour of cancer, and therefore to
facilitate treatment planning.
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Introduction
Pre-operative/pretreatment biopsies are widely used
as diagnostic tools of different epithelial tumours, and
they are also used to determine the histological subtype
and degree of differentiation. The possibility to use
diagnostic biopsies to identify tumours with aggressive
behaviour is crucial for proper treatment planning.
Such aggressive behaviour is associated with unfa-
vourable histology. Unfortunately, the small amount of
tumour tissue in the biopsy (compared with postopera-
tive samples) can impede identification of some
histopathological markers (e.g. perineural invasion).
Moreover, a superficial diagnostic biopsy may not
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include histopathological features in the deep regions
of tumours. Therefore, it is of clinical interest to identify
reliable and simple prognostic marker(s) that can be
evaluated in diagnostic biopsies, particularly
histopathological parameters that can be identified in
routine haematoxylin and eosin (H&E) slides.
Tumour budding, or sprouting (Figure 1), is a
histopathological phenomenon that refers to the pres-
ence of single cancer cell(s) or small cluster(s) of up
to four cancer cells that are separated from the main
part of the tumour. It was speculated that tumour
budding is the result of interactions between cancer
cells and tumour microenvironment.1 Tumour bud-
ding represents active invasion, dissociation and
epithelial–mesenchymal transition.1,2 A relationship
to cancer stem cells3 has also been reported. Recent
and rapidly accumulating data indicate that tumour
budding may open new perspectives for prognostica-
tion and treatment planning of many cancers.2,4–7
The prognostic value of tumour budding in diagnostic
biopsies has been examined in recent studies.8–10 In
addition, some of these studies reported the concor-
dance of the score of tumour budding in pre-operative
diagnostic biopsy samples and postoperative surgical
specimens.11,12 However, the implementation of
tumour budding for pathology reports and treatment
planning still requires further studies.2,13
We conducted a systematic review of studies that
evaluated tumour budding in diagnostic specimens to
summarise the current understanding of this topic
and to guide pathologists in reporting this histopatho-
logical feature in daily practice.
Methods
S E A R C H P R O T O C O L
We systematically retrieved all studies that evalu-
ated tumour budding in pretreatment diagnostic
biopsies. The systematic search included databases
of PubMed, OvidMedline, Scopus, Web of Science
and Cochrane library from their inception until
March 2018. The search strategy was developed by
combining the search terms: ‘Tumour budding’
AND ‘biopsy’. Additional search using (‘Tumour
budding’) AND (‘diagnostic biopsy’ OR ‘pretreatment
biopsy’ OR ‘preoperative sample’) was also con-
ducted. References of the eligible studies were
searched manually to enhance the inclusion of all
relevant studies. The Preferred Reporting Items for
A
C D
B
Figure 1. Tumour budding (arrows) in a pre-operative diagnostic biopsy of colorectal cancer. A, Tumour budding (haematoxylin and eosin-
stained section) in the area inside the insert, which is magnified in B. C, Tumour budding (pancytokeratin-stained section) in the area inside
the insert, which is magnified in D.
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Systematic Review and Meta-Analysis (PRISMA)14
guidelines were followed.
I N C L U S I O N A N D E X C L U S I O N C R I T E R I A
All original reports that used pretreatment biopsies in
assessment of tumour budding were included. Eligible
studies must have evaluated tumour budding in diag-
nostic biopsies of a cohort. Review articles, case
reports, case series, conference abstracts, editorials,
letters to the editor and commentaries were excluded.
Our search was limited to articles in the English lan-
guage.
S C R E E N I N G
Two independent researchers (A.A., O.Y.) performed
the screening of retrieved studies at all stages to iden-
tify the eligible studies. Any disagreements between
the two researchers were resolved by discussion to
reach a consensus on which studies should be
included or excluded.
D A T A E X T R A C T I O N
We retrieved the basic information (name of the first
author, publication year, country, number of cases,
stage, type of tumour and main treatment) from all
eligible studies. Data regarding assessment of tumour
budding included the definition of buds, cut-off point,
microscopic magnification, staining and main find-
ings.
Q U A L I T Y A S S E S S M E N T
As tumour budding is a prognostic marker, we used
the guidelines of reporting recommendations for
tumour marker prognostic studies (REMARK)15 to
assess the quality of the studies. The main criteria of
REMARK guidelines are selected and summarised in
Table 1.
Results
Our search retrieved 13 studies (11 cohorts) that
evaluated tumour budding in pretreatment diagnostic
biopsies (Figure 2). The findings of these studies
(Table 2) indicated that tumour budding is an evalu-
able histopathological parameter in biopsy specimens
and could be used as a reliable prognosticator for
patient survival. The studies evaluated tumour bud-
ding in pretreatment samples in the following
cancers: five studies (four cohorts) on rectal
cancer,8,16–19 two on colorectal cancer9,11 and three
(two cohorts) on oral cancer.10,12,20 There was one
study on breast cancer,13 one on epidermoid anal
cancer21 and one on cancer of the external auditory
canal.22
In colorectal cancer, the studies (of rectal and col-
orectal cohorts) showed that the pre-operative score
of tumour budding was associated with lymph node
metastasis,8,9,11,16,17,19 distant metastasis9,11,19 and
patient survival.8,19 The relationship between pre-
operative tumour budding and the presence of extra-
nodal tumour deposits,17 lymphovascular invasion,9
tumour grade11 and stage9 was also reported in col-
orectal cancer. In oral cancer, pre-operative tumour
budding had a significant prognostic value for lymph
node metastasis, overall survival and relapse-free sur-
vival.10,20 Pre-operative tumour budding in oral can-
cer also had strong correlations with tumour grade,
tumour depth and blood vessel invasion.10,20 In
breast cancer, tumour budding is associated with
venous invasion.13 A study of epidermoid anal cancer
revealed that pretreatment tumour budding was a
significant predictor of overall survival.21 In cancer of
the external auditory canal, a single study showed
that pretreatment tumour budding is associated with
expression of laminin 5-c2 and predicts disease-speci-
fic survival.22 Of note, a significant correlation
between tumour budding in pre-operative biopsies
and postoperative samples was reported in colorectal
cancer,,11 breast cancer13 and oral cancer.12,20
The quality of the published studies was assessed
as satisfactory to good. Some studies did not follow
the REMARK guidelines correctly (Table 2), as they
reported the prognostic value of tumour budding
without multivariate analysis or did not analyse the
relationship between tumour budding and classic
prognostic factors (e.g. stage, grade, depth of inva-
sion). Some of the published studies suffered from the
limitations posed by a low number of cases.11,17,19,22
Discussion
Tumour budding is a hallmark of cancer invasion
and has been recently validated as a promising prog-
nostic marker in colon cancer,23 oesophageal can-
cer,24 pancreatic cancer,25 lung cancer7 and oral
cancer.26 Interestingly, the meta-analyses conducted
on the published studies confirm the prognostic value
of tumour budding in oesophageal, colorectal and
oral cancers.2,4,5 Moreover, tumour budding is cur-
rently considered as an additional prognosticator by
© 2018 John Wiley & Sons Ltd, Histopathology, 74, 536–544.
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the Union for International Cancer Control’s tumour–
necrosis–metastasis (TNM) classification.1,27 The
assessment of tumour budding in pretreatment diag-
nostic biopsies has been recently investigated by
many researchers. Here, for the first time to our
knowledge, we systematically reviewed the literature
to summarise the evidence on pretreatment assess-
ment of tumour budding. The published studies
showed that evaluation of tumour budding was appli-
cable to pretreatment diagnostic biopsies of oral,
breast, colorectal, epidermoid anal and external audi-
tory canal cancers.
The first study that evaluated tumour budding in
pre-operative/pretreatment biopsies was published in
1989 by Morodomi and colleagues on a cohort of
rectal cancer patients.16 Notably, most of the studies
that evaluated tumour budding in pre-operative biop-
sies were on colorectal cancer (Table 2), where a
strong correlation between tumour budding and
lymph node metastasis has been observed.9,28 The
ability of tumour budding to prognosticate nodal
metastasis has also been reported in other can-
cers.2,29 Moreover, the prognostic impact of tumour
budding for nodal metastasis, patient survival or both
was prominent in the early stages of other
cancers.30–32 These findings indicate that tumour
budding is an important step in the development of
metastasis.
The international tumour budding consensus con-
ference 2016 (ITBCC 2016) introduced guidelines to
standardise the scoring system of this prognostic mar-
ker in colorectal cancer.33 Interestingly, a recent
study on pancreatic cancer25 used the aforementioned
ITBCC evaluation method of ITBCC 2016, and found
that this method represents a simple and standardised
scoring system that facilitates inclusion of tumour bud-
ding in pathology reports. The recommendations
included 11 statements,33 starting with a definition of
tumour budding in colorectal cancer as: ‘a single
tumour cell or a cell cluster consisting of four tumour
cells or less’ and ending with a statement indicating
that: ‘Tumour budding and tumour grade are not the
same’. There were recommendations specific for prog-
nostic significance of tumour budding in colorectal
cancer indicating that: ‘Tumour budding is an inde-
pendent predictor of lymph node metastasis in pT1
Table 1. Items adapted from REMARK that were used to assess the quality of studies on tumour budding in preoperative
biopsies
Item Criteria
Introduction • The hypothesis about tumour budding and objectives of the study were explained
Study design • Retrospective or prospective cohort with a well-defined study population
• Medical treatment of the cases was explained
Material • Patient data such as age, gender, clinical stage and WHO grade were explained
Method of evaluation • Well-described method including the microscopic field/s and the cutoff point
• Routine HE-staining and/or immunohistochemistry (e.g. pan-cytokeratin (AE1/AE3))
Data analysis • The survival endpoint was well defined
• Estimated effect (e.g. hazard ratio, with confidence intervals) of preoperative tumour
budding was reported
• Univariate estimate: reported the effect of tumour budding in pretreatment samples on
outcome
• Multivariate estimate: adjusted for the conventional prognostic factors
• Inter-observer variability was evaluated
• The relationship between the pretreatment score of tumour budding and conventional
prognosticators was reported
• The prognostic value of the classical prognostic factors (e.g. stage and grade) were
reported
Discussion • The results about tumour budding were discussed in the context of the relevant studies
• The limitations of the study were explained
• Recommendation for further evaluation of tumour budding was suggested based on
published guidelines
© 2018 John Wiley & Sons Ltd, Histopathology, 74, 536–544.
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colorectal cancer, and for survival in stage II colorectal
cancer’. We noted that the majority of the relevant
studies were in accordance with the main recommen-
dations especially in colorectal cancer studies
(Table 2). It is important to take into consideration
that the studies included in our systematic review were
not limited to colorectal cancer. In addition, the
authors of the recommendations33 stated that the
ITBCC is not an end-point, but rather a step towards
further research.33 Therefore, it is necessary for future
research to follow the introduced guidelines and
update them if needed for each specific cancer type.
Tumour budding evaluated on H&E-stained slides
has shown a reliable predictive value.34–36 This simple
method has the potential to make the evaluation of
tumour budding more applicable to daily practice than
the use of biomarkers that require immunohistochemi-
cal staining. It has been stated in the recent recommen-
dation (ITBCC 2016)33 that: ‘Tumour budding is
counted on HE’ because a majority of the published data
were based on H&E assessment. Also, the low cost of
H&E staining is a factor that allows a worldwide evalua-
tion of tumour budding. The ITBCC group admitted that
this can change if future data on immunohistochemical
assessment indicate it to be superior to H&E staining.33
Of note, Kai and colleagues37 compared the usefulness
of cytokeratin staining compared with H&E staining (in
postoperative samples of colorectal cancer) and found
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Figure 2. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart. Number of articles included and
excluded along the steps of systematic searching for studies that examined tumour budding in pretreatment diagnostic biopsies.
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that cytokeratin staining was useful in the evaluation of
tumour budding by unexperienced pathologists, but for
expert pathologists the benefit of using cytokeratin was
only slight. In oral squamous cell carcinoma, evaluation
of tumour budding using cytokeratin produced higher
reproducibility than H&E staining, and interobserver
variation was higher among less experienced examin-
ers.38 Indeed, while pan-cytokeratin staining can detect
more tumour budding,39 H&E staining has been used
successfully in several studies with good reliability and
reproducibility.11,25,30 Thus, at present routine assess-
ment of tumour budding with H&E staining can be
used, while pan-cytokeratin staining may be considered
in selected cases. For example, immunostaining could
be used if there is a high density of inflammatory infil-
trate preventing accurate evaluation of tumour bud-
ding.
A satisfactory biopsy is necessary for appropriate
evaluation of tumour budding. A histopathological
study on pre-operative biopsies in colorectal cancer
reported that cases where at least three biopsies had
been taken yielded satisfactory results in assessment of
poorly differentiated tumour clusters of five cancer
cells or more.40 Such a procedure of multiple biopsies
might be necessary for representative samples. How-
ever, excessive fragmentation of the specimens, arte-
facts, effects of tangential biopsies and the presence of
extensive necrosis often reduce the quality of pretreat-
ment diagnostic biopsies, and these can prevent a
proper assessment of tumour budding. Interestingly,
intratumoural budding (i.e. buds within the tumour
centre) correlated significantly with peritumoural bud-
ding at the invasive front.41,42 Diagnostic biopsies
often do not include the invasive front, and it is also
challenging to identify this area from small biopsies.
Due to this fact, it seems more reliable to analyse
intratumoural budding in these diagnostic speci-
mens.11
In conclusion, our systematic review revealed that
tumour budding could be successfully evaluated in
diagnostic biopsies. The published studies had some
limitations; they were mainly retrospective in nature
and were commonly based on a single-institution expe-
rience. Due to heterogeneity between tumour types in
the published studies, we were not able to perform
meta-analyses. Therefore, the finding of our systematic
review is still preliminary, and requires further valida-
tion and multicentre collaborative efforts. Of note, the
finding was consistent between all eligible studies, indi-
cating that tumour budding is an evaluable marker in
diagnostic biopsy specimens and has a significant prog-
nostic value. Thus, the current evidence summarised
in our systematic review can be used as a starting-
point for future research. Such research should aim to
define distinctive criteria for assessment of tumour bud-
ding in diagnostic biopsies, and to be considered in
therapeutic decision-making.
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